UY34785A - Formulación en cápsulas solubilizadas de [(1s)-1-{[(2s,4r)-4-(7-cloro-4metoxiisoquinolin-1-iloxi)-2-({(1r,2s)-1-[(ciclopropilsulfonil)carbamoil]-2-etenilciclopropil}carbamoil)pirrolidin-1-il]carbonil}-2,2-dimetilpropil]carbamato de 1,1-dimetiletilo - Google Patents

Formulación en cápsulas solubilizadas de [(1s)-1-{[(2s,4r)-4-(7-cloro-4metoxiisoquinolin-1-iloxi)-2-({(1r,2s)-1-[(ciclopropilsulfonil)carbamoil]-2-etenilciclopropil}carbamoil)pirrolidin-1-il]carbonil}-2,2-dimetilpropil]carbamato de 1,1-dimetiletilo

Info

Publication number
UY34785A
UY34785A UY0001034785A UY34785A UY34785A UY 34785 A UY34785 A UY 34785A UY 0001034785 A UY0001034785 A UY 0001034785A UY 34785 A UY34785 A UY 34785A UY 34785 A UY34785 A UY 34785A
Authority
UY
Uruguay
Prior art keywords
carbamoil
ciclopropilsulfonil
cyclopropil
iloxi
pirrolidin
Prior art date
Application number
UY0001034785A
Other languages
English (en)
Spanish (es)
Inventor
Robert Kevin Perrone
Original Assignee
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48428670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34785(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware filed Critical Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware
Publication of UY34785A publication Critical patent/UY34785A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY0001034785A 2012-05-07 2013-05-06 Formulación en cápsulas solubilizadas de [(1s)-1-{[(2s,4r)-4-(7-cloro-4metoxiisoquinolin-1-iloxi)-2-({(1r,2s)-1-[(ciclopropilsulfonil)carbamoil]-2-etenilciclopropil}carbamoil)pirrolidin-1-il]carbonil}-2,2-dimetilpropil]carbamato de 1,1-dimetiletilo UY34785A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261643454P 2012-05-07 2012-05-07

Publications (1)

Publication Number Publication Date
UY34785A true UY34785A (es) 2013-11-29

Family

ID=48428670

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034785A UY34785A (es) 2012-05-07 2013-05-06 Formulación en cápsulas solubilizadas de [(1s)-1-{[(2s,4r)-4-(7-cloro-4metoxiisoquinolin-1-iloxi)-2-({(1r,2s)-1-[(ciclopropilsulfonil)carbamoil]-2-etenilciclopropil}carbamoil)pirrolidin-1-il]carbonil}-2,2-dimetilpropil]carbamato de 1,1-dimetiletilo

Country Status (33)

Country Link
US (1) US20130302414A1 (enExample)
EP (1) EP2846780B1 (enExample)
JP (1) JP6276756B2 (enExample)
KR (1) KR20150004921A (enExample)
CN (1) CN104363899A (enExample)
AR (1) AR090954A1 (enExample)
AU (1) AU2013260005B2 (enExample)
BR (1) BR112014027676A2 (enExample)
CA (1) CA2872765A1 (enExample)
CL (1) CL2014003012A1 (enExample)
CO (1) CO7141457A2 (enExample)
CY (1) CY1120756T1 (enExample)
DK (1) DK2846780T3 (enExample)
EA (1) EA028749B1 (enExample)
ES (1) ES2688817T3 (enExample)
HR (1) HRP20181583T1 (enExample)
IL (1) IL235466B (enExample)
LT (1) LT2846780T (enExample)
MX (1) MX358545B (enExample)
MY (1) MY171378A (enExample)
NZ (1) NZ630248A (enExample)
PE (1) PE20142439A1 (enExample)
PH (1) PH12014502405A1 (enExample)
PL (1) PL2846780T3 (enExample)
PT (1) PT2846780T (enExample)
RS (1) RS57881B1 (enExample)
SG (1) SG11201406964QA (enExample)
SI (1) SI2846780T1 (enExample)
SM (1) SMT201800506T1 (enExample)
TW (1) TWI577392B (enExample)
UY (1) UY34785A (enExample)
WO (1) WO2013169520A1 (enExample)
ZA (1) ZA201408967B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013169577A1 (en) * 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
US9499550B2 (en) 2012-10-19 2016-11-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
WO2019130341A1 (en) * 2017-12-26 2019-07-04 Hetero Labs Limited Capsule compositions comprising lopinavir and ritonavir
PL3765024T3 (pl) 2018-03-14 2024-08-05 KaNDy Therapeutics Limited <div>Nowa formulacja farmaceutyczna zawierająca podwójnych antagonistów receptora nk-1/nk-3</div>
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
EE200300201A (et) * 2000-10-31 2003-08-15 Boehringer Ingelheim Pharmaceuticals, Inc. Püranoonsete proteaasi inhibiitorite iseemulgeeruva kompositsiooni oraalne doos
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
TWI480272B (zh) * 2008-10-09 2015-04-11 Anadys Pharmaceuticals Inc 藉由５，６－二氫－１ｈ－吡啶－２－酮與一或多種其他抗病毒化合物的組合物抑制ｃ型肝炎病毒的方法
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound

Also Published As

Publication number Publication date
HK1204552A1 (en) 2015-11-27
RS57881B1 (sr) 2019-01-31
MX358545B (es) 2018-08-24
TW201350145A (zh) 2013-12-16
MX2014013220A (es) 2015-05-11
CN104363899A (zh) 2015-02-18
PE20142439A1 (es) 2015-01-28
US20130302414A1 (en) 2013-11-14
WO2013169520A1 (en) 2013-11-14
PH12014502405A1 (en) 2015-01-12
EP2846780A1 (en) 2015-03-18
EA028749B1 (ru) 2017-12-29
PT2846780T (pt) 2018-10-26
LT2846780T (lt) 2018-11-12
AU2013260005B2 (en) 2017-07-13
SG11201406964QA (en) 2014-11-27
JP6276756B2 (ja) 2018-02-07
CL2014003012A1 (es) 2015-07-10
NZ630248A (en) 2016-11-25
EP2846780B1 (en) 2018-07-18
CY1120756T1 (el) 2019-12-11
SMT201800506T1 (it) 2018-11-09
HRP20181583T1 (hr) 2018-11-30
IL235466B (en) 2019-03-31
BR112014027676A2 (pt) 2017-06-27
ZA201408967B (en) 2016-10-26
AR090954A1 (es) 2014-12-17
AU2013260005A1 (en) 2015-01-15
KR20150004921A (ko) 2015-01-13
TWI577392B (zh) 2017-04-11
PL2846780T3 (pl) 2018-11-30
ES2688817T3 (es) 2018-11-07
MY171378A (en) 2019-10-10
CA2872765A1 (en) 2013-11-14
JP2015516418A (ja) 2015-06-11
DK2846780T3 (en) 2018-09-17
SI2846780T1 (sl) 2018-09-28
CO7141457A2 (es) 2014-12-12
EA201492039A1 (ru) 2015-02-27

Similar Documents

Publication Publication Date Title
UY34785A (es) Formulación en cápsulas solubilizadas de [(1s)-1-{[(2s,4r)-4-(7-cloro-4metoxiisoquinolin-1-iloxi)-2-({(1r,2s)-1-[(ciclopropilsulfonil)carbamoil]-2-etenilciclopropil}carbamoil)pirrolidin-1-il]carbonil}-2,2-dimetilpropil]carbamato de 1,1-dimetiletilo
AU2013225533A8 (en) Amido spirocyclic amide and sulfonamide derivatives
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201390843A1 (ru) Применение агониста toll-подобного рецептора для лечения рака
MY177242A (en) Imidazopyrrolidinone compounds
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
UA114726C2 (uk) 1,4-дизаміщені аналоги піридазину та способи лікування пов&#39;язаних з дефіцитом smn станів
EA201590931A1 (ru) Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций
EA201170227A1 (ru) Имидазолкарбоксамиды
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
WO2014052360A3 (en) Glycoprotein preparations
MX2013004061A (es) Analogos de ciclosporina.
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
EA201591024A1 (ru) Димерные соединения
EA201400822A1 (ru) Производные гетероциклических амидов в качестве антагонистов p2xрецептора
MA35816B1 (fr) Dérivés d&#39;aniline, leur préparation et leur application thérapeutique
BR112016028843A2 (pt) formas sólidas de um composto antiviral
MY169048A (en) Polymorph of n- (2-methoxybenzoyl) -4- [(methylaminocarbonyl) amino] benzenesulfonamide
EA201492029A1 (ru) N-этил-4-гидроксил-1-метил-5-(метил(2,3,4,5,6-пентагидроксигексил)амино)-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
EA201791354A3 (ru) Препараты производных пиримидиндиона
EA201400609A1 (ru) Твердые формы препаратов иматиниба, ресуспензируемые непосредственно перед применением
MA35943B1 (fr) Utilisation de (rs)-s-cyclopropyl-s-(4-{[4-{ [(1r, 2r)-2-hydroxy-1-méthylpropyl]oxy}-5-(trifluorméthyl) pyrimidin-2-yl]amino}
RU2009132625A (ru) Способ лечения заболеваний, вызываемых вирусом герпеса